Perhaps it's a sign of how desperate the pharmaceutical industry has become for relief from its regulatory burden. Or maybe it's just the kind of founder credibility that opens checkbooks in a risk-averse funding climate.
Either way, Collate—a startup applying artificial intelligence to the soul-crushing task of regulatory paperwork in life sciences—has pulled in $95 million in Series A funding, the company disclosed June 3, 2026. Redpoint Ventures led the round, joined by First Round Capital, CRV, Conviction, and Y Combinator. Forbes pegged the post-money valuation at approaching $1 billion.
That's a remarkable leap for a company that CEO Surbhi Sarna launched in early 2025.
The financing brings Collate's total raised to $125 million, following a $30 million seed round announced January 13, 2025 (also led by Redpoint, which valued the company north of $100 million even then). At the time, the startup was still months away from shipping its first commercial product.
Betting on a Known Quantity
Investors are wagering on more than just the technology. Sarna, a former partner at Y Combinator, founded nVision Medical—a medical device company that Boston Scientific acquired in 2018. Her co-founder and CTO, Nate Smith, comes with his own exit: he built and sold Lever, where he served as co-founder, CEO, and CTO before Employ scooped it up.
It's the kind of résumé that matters when you're asking VCs to believe you can navigate both the labyrinthine world of FDA compliance and the equally complex challenge of selling enterprise software to an industry not known for moving fast.
The combination appears to be working.
Fifty Customers, One Year In
Collate shipped its first commercial product in May 2025. Since then, according to Forbes, it has signed roughly 50 customers—a roster that includes large pharmaceutical companies, major medical device manufacturers, and publicly traded biotech firms. Not bad for a platform barely into its second year.
What Collate does isn't glamorous, but it's necessary. The life sciences sector churns out staggering volumes of regulated documentation: research and development reports, clinical trial protocols, quality assurance logs, regulatory submissions. The process traditionally demands armies of specialized writers and compliance professionals, all working to satisfy the FDA and international regulatory bodies.
Collate's AI aims to automate much of that. Speed up the paperwork. Cut costs. All while maintaining the exacting compliance standards that define one of the world's most tightly regulated industries.
Whether the technology can deliver on that promise at scale remains an open question, though early customers seem willing to find out.
The Compliance Infrastructure Problem
There's a reason this space is hard. Pharmaceutical and biotech companies don't just need software—they need software they can trust with sensitive clinical data, proprietary research, and documents that regulators will scrutinize line by line.
Collate's security documentation, dated March 2025, lays out enterprise-grade protections, including zero-day data retention policies with AI providers like OpenAI and Anthropic. Table stakes, perhaps, but critical ones for companies handling information that could mean the difference between FDA approval and years of additional trials.
The near-unicorn valuation suggests that investors see a massive market if Collate can crack the code. Regulatory complexity isn't shrinking—if anything, it's expanding as global markets impose overlapping requirements. For companies already stretched thin by compliance demands, automation isn't a luxury. It's survival.
What a $95 Million War Chest Buys
With this kind of capital, Collate can do what most Series A companies only dream of: expand aggressively, hire deeply, and build out a platform before competitors catch up. The round ranks among the heftier Series A raises in vertical AI for 2026—a category that's seen plenty of hype but fewer breakout successes.
The real test will come as Collate scales beyond its first 50 customers and into the broader market. Can the platform handle the full range of regulatory documentation across different therapeutic areas and geographies? Will pharmaceutical giants, notoriously cautious about new technology, embrace AI-generated compliance documents?
Those questions don't have answers yet. But for now, at least, the bet is that Sarna and her team have the experience, the technology, and the timing to transform one of the least automated corners of modern business. And for an industry drowning in paperwork, that transformation would be more than welcome—it would be overdue.
